Next Article in Journal
Rapid Alpha-Synuclein Toxicity in a Neural Cell Model and Its Rescue by a Stearoyl-CoA Desaturase Inhibitor
Next Article in Special Issue
Antibody-Drug Conjugates: The New Frontier of Chemotherapy
Previous Article in Journal
Molecular and Functional Analysis of Choline Transporters and Antitumor Effects of Choline Transporter-Like Protein 1 Inhibitors in Human Pancreatic Cancer Cells
Previous Article in Special Issue
CD38 and Anti-CD38 Monoclonal Antibodies in AL Amyloidosis: Targeting Plasma Cells and beyond
Open AccessReview

B-Cell Maturation Antigen (BCMA) as a Target for New Drug Development in Relapsed and/or Refractory Multiple Myeloma

Department of Pharmaceutical Sciences, Wayne State University, Detroit, MI 48202, USA
Int. J. Mol. Sci. 2020, 21(15), 5192; https://doi.org/10.3390/ijms21155192
Received: 2 July 2020 / Revised: 19 July 2020 / Accepted: 20 July 2020 / Published: 22 July 2020
During the past two decades there has been a major shift in the choice of agents to treat multiple myeloma, whether newly diagnosed or in the relapsed/refractory stage. The introduction of new drug classes, such as proteasome inhibitors, immunomodulators, and anti-CD38 and anti-SLAMF7 monoclonal antibodies, coupled with autologous stem cell transplantation, has approximately doubled the disease’s five-year survival rate. However, this positive news is tempered by the realization that these measures are not curative and patients eventually relapse and/or become resistant to the drug’s effects. Thus, there is a need to discover newer myeloma-driving molecular markers and develop innovative drugs designed to precisely regulate the actions of such putative targets. B cell maturation antigen (BCMA), which is found almost exclusively on the surfaces of malignant plasma cells to the exclusion of other cell types, including their normal counterparts, has emerged as a specific target of interest in this regard. Immunotherapeutic agents have been at the forefront of research designed to block BCMA activity. These agents encompass monoclonal antibodies, such as the drug conjugate belantamab mafodotin; bispecific T-cell engager strategies exemplified by AMG 420; and chimeric antigen receptor (CAR) T-cell therapeutics that include idecabtagene vicleucel (bb2121) and JNJ-68284528. View Full-Text
Keywords: myeloma; BCMA; bispecific T-cell engager; antibody-drug conjugates; chimeric antigen receptor T-cells; belantamab mafodotin; idecabtagene vicleucel; JNJ-68284528 myeloma; BCMA; bispecific T-cell engager; antibody-drug conjugates; chimeric antigen receptor T-cells; belantamab mafodotin; idecabtagene vicleucel; JNJ-68284528
Show Figures

Figure 1

MDPI and ACS Style

Abramson, H.N. B-Cell Maturation Antigen (BCMA) as a Target for New Drug Development in Relapsed and/or Refractory Multiple Myeloma. Int. J. Mol. Sci. 2020, 21, 5192.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop